Price$2.20-0.47 (-17.60%)
2026-03-042026-06-05
News · 26 weeks310%
2025-12-142026-06-07
Mix1790d
- Other11(65%)
- SEC Filings6(35%)
Latest news
25 items- PRHeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared AlgorithmSouthlake, TX, June 02, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced the commercial release of MyoVista Insights™ version 1.3, a major platform update that introduces the MyoVista Insights AI-ECG Algorithm Marketplace. The Marketplace enables third-party algorithm results to be integrated into the MyoVista Insights platform, beginning with an FDA-cleared AI-ECG model from Bunkerhill Health. The Bunkerhill ECG-EF model enables clinicians to detect reduc
- SECSEC Form 253G2 filed by HeartSciences Inc.253G2 - HeartSciences Inc. (0001468492) (Filer)
- PRHeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health NetworkSouthlake, TX, May 19, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that it has entered into a commercial agreement with North Shore Health, a community hospital serving Cook County, Minnesota and the surrounding region, to deploy the MyoVista Insights™ platform. North Shore Health is part of the Cibolo Rural Health Networks ("Cibolo Health") network, which previously selected MyoVista Insights as its endorsed ECG management platform for hospitals wit
- SECHeartSciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HeartSciences Inc. (0001468492) (Filer)
- PRHeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™Southlake, TX, May 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that it has signed a commercial agreement with St. Vincent Health, a Critical Access Hospital serving Lake County, Colorado, to deploy the MyoVista Insights™ platform. The agreement marks an important commercial milestone for HeartSciences, representing the Company's first mainstream revenue-generating deployment of MyoVista Insights, building on previously announced reference and ear
- SECSEC Form QUALIF filed by HeartSciences Inc.QUALIF - HeartSciences Inc. (0001468492) (Filer)
- SECSEC Form 253G2 filed by HeartSciences Inc.253G2 - HeartSciences Inc. (0001468492) (Filer)
- PRHeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders MeetingSouthlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company") a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the "Annual Meeting") which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences' outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the
- SECSEC Form 1-A POS filed by HeartSciences Inc.1-A POS - HeartSciences Inc. (0001468492) (Filer)
- SECHeartSciences Inc. filed SEC Form 8-K: Leadership Update8-K - HeartSciences Inc. (0001468492) (Filer)
- PRHeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System CategorySouthlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including
- PRHeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor MeetingsSouthlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET. Hosted by Investor Summit Group, a premier platform connecting microcap companies with leading investors, the event provides a highly efficient forum for emerging growth companies to engage directly with institutional investors, family offices, and high-net-worth individuals. Event Details: Conference: Inves
- SECSEC Form DEFA14A filed by HeartSciences Inc.DEFA14A - HeartSciences Inc. (0001468492) (Filer)
- SECSEC Form DEF 14A filed by HeartSciences Inc.DEF 14A - HeartSciences Inc. (0001468492) (Filer)
- SECHeartSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HeartSciences Inc. (0001468492) (Filer)
- PRHeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateSouthlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today reported financial results for its fiscal third quarter ended January 31, 2026 ("FQ3 2026") and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administra
- SECSEC Form 10-Q filed by HeartSciences Inc.10-Q - HeartSciences Inc. (0001468492) (Filer)
- SECSEC Form PRE 14A filed by HeartSciences Inc.PRE 14A - HeartSciences Inc. (0001468492) (Filer)
- PRUniversity of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference CenterSouthlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS; HSCSW), HSCSW) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that the University of the West of England ("UWE") has adopted the Company's MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology. Under the agreement, MyoVista Insights and the MyoVista wavECG device will be used exclusively across UWE's cardiac and physiological science teaching pro
- PRCibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent HospitalsSouthlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that Cibolo Rural Health Networks ("Cibolo Health") has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high-value networks. This collaboration will provide Cibolo Health's network of 123 independent hospitals across six states with access to a modern, cloud-native ECG management platform designed to improve workflow efficienc
- SECHeartSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - HeartSciences Inc. (0001468492) (Filer)
- INSIDERSEC Form 4 filed by Director Wells David R.4 - HeartSciences Inc. (0001468492) (Issuer)
- INSIDERSEC Form 4 filed by Director Bent Bruce4 - HeartSciences Inc. (0001468492) (Issuer)
- INSIDERSEC Form 4 filed by Officer Hilz Mark T4 - HeartSciences Inc. (0001468492) (Issuer)
- INSIDERSEC Form 4 filed by Director Szymczak Brian4 - HeartSciences Inc. (0001468492) (Issuer)
HSCS FAQ
5 questionsWhere does HSCS stock trade?
HeartSciences Inc. (HSCS) is listed on NASDAQ.What sector and industry is HSCS in?
HeartSciences Inc. operates in the Health Care sector, Industrial Specialties industry.When did HeartSciences Inc. go public?
HeartSciences Inc. (HSCS) completed its IPO in 2022.What companies are similar to HSCS?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare HSCS side-by-side with any of them on Quantisnow.How can I track HSCS on Quantisnow?
Quantisnow aggregates HeartSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HSCS to receive live email and push alerts on every new disclosure.